跳至主要内容
临床试验/NCT02610153
NCT02610153已完成不适用

A Prospective Observational Study Assessing the Management of Anticoagulation With Vitamin K Antagonists in Patients With Nonvalvular Atrial Fibrillation Treated in Cardiology Practices

Bayer0 个研究点目标入组 1,013 人开始时间: 2015年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
1,013
主要终点
International Normalized Ratio (INR) Time in Therapeutic Range (TTR)

研究概览

简要总结

This prospective observational study is to assess the predictive factors of poor control of international normalized ratio (INR) to determine the treatment strategies received by patients with a poor control of INR in real-life clinical practice and to explore the effectiveness and safety of these strategies in patients with non-valvular atrial fibrillation who start vitamin K antagonist (VKA) treatment

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged ≥ 18 years.
  • Patients with a diagnosis of nonvalvular atrial fibrillation according to the criteria of the Spanish Agency of Medicines and Medical Devices (AEMPS) (2013) who are treated in cardiology practices.
  • Patients about to start treatment with a vitamin K antagonist or who are in the first two months of treatment.
  • Patients for whom access to at least 80% of INR tests performed during treatment with vitamin K antagonists is expected to be available.
  • Patients with the mental and physical capacity to complete the study questionnaires and give their informed consent to participate in the study.

排除标准

  • Patients with mitral stenosis or another significant valve disease for which specific treatment is scheduled or has already been performed (prosthesis or valvuloplasty).
  • Patients hospitalised at the time of inclusion in the study.
  • Patients with a life expectancy of less than 13 months.
  • Patients who are participating in a clinical trial.
  • Patients receiving double antiplatelet therapy.

研究组 & 干预措施

Cohort 1

Adult patients, diagnosed with no-valvular atrial fibrillation and who have recently initiated or are going to initiate VKA treatment, that attend the Cardiology Units

干预措施: Vitamin K Antagonist (Drug)

结局指标

主要结局

International Normalized Ratio (INR) Time in Therapeutic Range (TTR)

时间窗: Up to 24 months

Percentage of time within an INR range of 2-3 estimated using the Rosendaal method

次要结局

  • Baseline thromboembolic risk based on the CHADS2 scale(Baseline)
  • Baseline thromboembolic risk based on the CHA2DS2-VASc scale(Baseline)
  • Baseline haemorrhagic risk based on the HAS-BLED scale(Baseline)
  • Changes in INR time in therapeutic range(Up to 24 months)
  • Patient preferences with regard to anticoagulant treatment based on patients' questionnaires(Up to 12 months)
  • Adherence to the anticoagulant treatment: Morisky-Green test(Up to 12 months)
  • Number and type of visits by patients to health professionals related to their anticoagulant treatment(Up to 12 months)
  • Number of patients using anticoagulant treatment strategies(Up to 24 months)
  • Number of patients treated according to clinical practice guidelines based on the Spanish Agency of Medicines and Medical Devices (AEMPS) therapeutic positioning report(Up to 24 months)
  • Number of thromboembolic events in patients with inadequate anticoagulation management(Up to 24 months)
  • Number of haemorrhagic events in patients with inadequate anticoagulation management(Up to 24 months)
  • Satisfaction with the anticoagulant treatment based on the Anti-Clot Treatment Scale (ACTS)(Up to 12 months)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验